This publication is an update to the questions-and-answers document published in May 2017. This update and others yet to come, will include additional information on how Brexit will affect marketing applications and authorizations for different types of medicinal products. The guidance relates to both human and veterinary medicines and, with this update, now includes new information for manufacturers of orphan drugs, generics and biosimilars, as well as hybrid medicines that rely on data from reference products and new clinical trial findings.

The guidance specifies that sponsors will no longer need to account for UK patients in the disease’s prevalence when calculating for orphan designations. They will only need to consider the requirement that the disease does not affect more than 5 in 10,000 people in the new EU of which the UK is not a part.

The EU urges companies to stay up-to-date and regularly check the EMA webpage dedicated to the consequences of Brexit.

Related articles
EC publishes biosimilar Q&A document for patients in 23 languages

NHS England to increase biosimilar usage

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.